Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.05 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

41 42 Next >

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

August 04, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

July 30, 2026

From Pfizer Inc.

Via Business Wire

What Health Experts Want You to Know About Pneumococcal Pneumonia

July 30, 2026

Via StatePoint Media

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

July 29, 2026

From Pfizer Inc.

Via Business Wire

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

July 22, 2026

From Pfizer Inc.

Via Business Wire

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

July 10, 2026

From Pfizer Inc.

Via Business Wire

OS Therapies Appoints Dr. Craig Eagle to Board of Directors

July 02, 2026

Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile...

Via Newsfile

Pfizer Declares Third-Quarter 2026 Dividend

June 24, 2026

From Pfizer Inc.

Via Business Wire

FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

June 24, 2026

From Pfizer Inc.

Via Business Wire

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

Via Investor Brand Network

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

June 24, 2026

Via Investor Brand Network

Topics Artificial Intelligence

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

June 24, 2026

From BioMedWire

Via GlobeNewswire

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

June 23, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

June 22, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Announces Chief Financial Officer Transition

June 18, 2026

From Pfizer Inc.

Via Business Wire

Consumer Watchdog Honors Michael A. Kelly with 2026 Lifetime Legal Achievement Award

June 17, 2026

June 17, 2026 -- The award recognizes distinguished attorneys and public-interest advocates whose careers have advanced consumer protection, challenged corporate misconduct, and improved public...

Via 24-7 Press Release

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

June 08, 2026

From Pfizer Inc.

Via Business Wire

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

June 06, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 01, 2026

From Pfizer Inc.

Via Business Wire

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026

From Pfizer Inc.

Via Business Wire

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026

From Pfizer Inc.

Via Business Wire

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026

From Pfizer Inc.

Via Business Wire

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026

From Pfizer Inc.

Via Business Wire

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026

From Pfizer Inc.

Via Business Wire

CK Life Sciences’ Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer

May 18, 2026

HONG KONG SAR - Media OutReach Newswire - 18 May 2026 - Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life...

Via MediaOutReach

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026

From Pfizer Inc.

Via Business Wire

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

May 12, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

May 12, 2026

Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors

From MarketNewsUpdates.com

Via GlobeNewswire

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026

From Arvinas Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.